bluuebunny/crossref_metadata_2025 huggingface dataset:
Table S4 from CARM1 Inhibition Enables Immunotherapy of Resistant Tumors by Dual Action on Tumor Cells and T Cells
Authors: Kumar Sushil , Zeng Zexian , Bagati Archis , Tay Rong En , Sanz Lionel A. , Hartono Stella R. , Ito Yoshinaga , Abderazzaq Fieda , Hatchi Elodie , Jiang Peng , Cartwright Adam N.R. , Olawoyin Olamide , Mathewson Nathan D. , Pyrdol Jason W. , Li Mamie Z. , Doench John G. , Booker Matthew A. , Tolstorukov Michael Y. , Elledge Stephen J. , Chédin Frédéric , Liu X. Shirley , Wucherpfennig Kai W.
Published: April 2023

Gene signature for investigating human cancer datasets
Supplementary Video S1 from Senescence Rewires Microenvironment Sensing to Facilitate Antitumor Immunity
Authors: Chen Hsuan-An , Ho Yu-Jui , Mezzadra Riccardo , Adrover Jose M. , Smolkin Ryan , Zhu Changyu , Woess Katharina , Bernstein Nicholas , Schmitt Georgia , Fong Linda , Luan Wei , Wuest Alexandra , Tian Sha , Li Xiang , Broderick Caroline , Hendrickson Ronald C. , Egeblad Mikala , Chen Zhenghao , Alonso-Curbelo Direna , Lowe Scott W.
Published: April 2023

Supplementary Video S1 from Senescence Rewires Microenvironment Sensing to Facilitate Antitumor Immunity
Supplementary Table S3 from Senescence Rewires Microenvironment Sensing to Facilitate Antitumor Immunity
Authors: Chen Hsuan-An , Ho Yu-Jui , Mezzadra Riccardo , Adrover Jose M. , Smolkin Ryan , Zhu Changyu , Woess Katharina , Bernstein Nicholas , Schmitt Georgia , Fong Linda , Luan Wei , Wuest Alexandra , Tian Sha , Li Xiang , Broderick Caroline , Hendrickson Ronald C. , Egeblad Mikala , Chen Zhenghao , Alonso-Curbelo Direna , Lowe Scott W.
Published: April 2023

Low (50 pg/ml) and high (1 ng/ml) dose of IFN-γ treatment in proliferating and senescent NSP cells.
Supplementary Table S2 from Senescence Rewires Microenvironment Sensing to Facilitate Antitumor Immunity
Authors: Chen Hsuan-An , Ho Yu-Jui , Mezzadra Riccardo , Adrover Jose M. , Smolkin Ryan , Zhu Changyu , Woess Katharina , Bernstein Nicholas , Schmitt Georgia , Fong Linda , Luan Wei , Wuest Alexandra , Tian Sha , Li Xiang , Broderick Caroline , Hendrickson Ronald C. , Egeblad Mikala , Chen Zhenghao , Alonso-Curbelo Direna , Lowe Scott W.
Published: April 2023

RNA-Seq data of proliferating (PRO) or senescent (SEN) NSP liver tumor cells, for both p53-restoration and drug-induced (trametinib+palbociclib) settings. PRO and SEN cells were also treated with the BET inhibitor JQ-1 (500 n, 48 h), to expose BRD4-mediated transcriptional output in each cellular state.
Supplementary Tables S1-S14 from Mutant NPM1 Directly Regulates Oncogenic Transcription in Acute Myeloid Leukemia
Authors: Uckelmann Hannah J. , Haarer Elena L. , Takeda Reina , Wong Eric M. , Hatton Charlie , Marinaccio Christian , Perner Florian , Rajput Masooma , Antonissen Noa J.C. , Wen Yanhe , Yang Lu , Brunetti Lorenzo , Chen Chun-Wei , Armstrong Scott A.
Published: April 2023

Table S1. Read normalized ratios of ChIPseq signal of untreated versus dTAG-13 treated OCI-AML3-NPM1c-FKBP12 cells.Table S2. Summary of NPM1c and NPM1 Chromatin Binding Targets.Table S3. Patient info for patient derived xenograft (PDX) models used.Table S4. ChIPseq reads per kilobase (rpk) data summary of PDX samples with NPM1c-Ab and NPM1-Ab.Table S5. RNAseq differential expression data of OCI-AML3-NPM1c-FKBP12 treated with dTag-13 for 3 or 24 h and OCI-AML3 cells treated with Selinexor for 6 h.Table S6. SLAMseq differential expression data of OCI-AML3-NPM1c-FKBP12 cells treated with dTag-13 for 15, 30, 60, 120 or 180 minutes.Table S7. PROseq differentially transcribed genes in OCI-AML3-NPM1c-FKBP12 cells treated with dTag-13 for 30 or 60 minutes and OCI-AML3 cells treated with VTP-50469 for 48 hours.Table S8. CRISPR tiling screen with NPM1 WT specific guides (blue) and NPM1c specific guides (red).Table S9. ChIPseq rpk values for CRM1 and HA ChIPs in 293T cells.Table S10. RNAseq differential gene expression analysis in 293T cells after overexpression of NPM1c-HA compared to all other samples (MIG, NPM1wt-HA and AS1-HA).Table S11. Fold change in ChIPseq differential peak interval signal in OCI-AML3 cells treated with Selinexor (100 nM, 6 hours) or VTP-50469 (330 nM, 96 hours).Table S12. Oligos used in this study.Table S13. Antibodies used in this study.Table S14. Summary of total and mapped reads of ChIPseq samples.
Supplementary tables from Discovery of Targets for Immune–Metabolic Antitumor Drugs Identifies Estrogen-Related Receptor Alpha
Authors: Sahu Avinash , Wang Xiaoman , Munson Phillip , Klomp Jan P.G. , Wang Xiaoqing , Gu Shengqing Stan , Han Ya , Qian Gege , Nicol Phillip , Zeng Zexian , Wang Chenfei , Tokheim Collin , Zhang Wubing , Fu Jingxin , Wang Jin , Nair Nishanth Ulhas , Rens Joost A.P. , Bourajjaj Meriem , Jansen Bas , Leenders Inge , Lemmers Jaap , Musters Mark , van Zanten Sanne , van Zelst Laura , Worthington Jenny , Liu Jun S. , Juric Dejan , Meyer Clifford A. , Oubrie Arthur , Liu X. Shirley , Fisher David E. , Flaherty Keith T.
Published: April 2023

S1: TFCRs of energy metabolism
S2: Bipotent TFCRs
S3: Log fold change of T-cell mediated killing upon knockout of OXPHOS genes
S4: Log fold change of MHC-I protien expression upon knockout of OXPHOS genes
S5: Bipotent TFCRs of angiogenesis
S6: Bipotent TFCRs of evasion of growth repressors
S7: Datasets included in Methods sections.
Figure S19 from Discovery of Targets for Immune–Metabolic Antitumor Drugs Identifies Estrogen-Related Receptor Alpha
Authors: Sahu Avinash , Wang Xiaoman , Munson Phillip , Klomp Jan P.G. , Wang Xiaoqing , Gu Shengqing Stan , Han Ya , Qian Gege , Nicol Phillip , Zeng Zexian , Wang Chenfei , Tokheim Collin , Zhang Wubing , Fu Jingxin , Wang Jin , Nair Nishanth Ulhas , Rens Joost A.P. , Bourajjaj Meriem , Jansen Bas , Leenders Inge , Lemmers Jaap , Musters Mark , van Zanten Sanne , van Zelst Laura , Worthington Jenny , Liu Jun S. , Juric Dejan , Meyer Clifford A. , Oubrie Arthur , Liu X. Shirley , Fisher David E. , Flaherty Keith T.
Published: April 2023

Expression of markers of M1 and M2 in scRNA data of ESRRAi and Vehicle treated mice.
Figure S16 from Discovery of Targets for Immune–Metabolic Antitumor Drugs Identifies Estrogen-Related Receptor Alpha
Authors: Sahu Avinash , Wang Xiaoman , Munson Phillip , Klomp Jan P.G. , Wang Xiaoqing , Gu Shengqing Stan , Han Ya , Qian Gege , Nicol Phillip , Zeng Zexian , Wang Chenfei , Tokheim Collin , Zhang Wubing , Fu Jingxin , Wang Jin , Nair Nishanth Ulhas , Rens Joost A.P. , Bourajjaj Meriem , Jansen Bas , Leenders Inge , Lemmers Jaap , Musters Mark , van Zanten Sanne , van Zelst Laura , Worthington Jenny , Liu Jun S. , Juric Dejan , Meyer Clifford A. , Oubrie Arthur , Liu X. Shirley , Fisher David E. , Flaherty Keith T.
Published: April 2023

Validation of bipotent regulators of angiogenesis or growth-suppressor.
Figure S14 from Discovery of Targets for Immune–Metabolic Antitumor Drugs Identifies Estrogen-Related Receptor Alpha
Authors: Sahu Avinash , Wang Xiaoman , Munson Phillip , Klomp Jan P.G. , Wang Xiaoqing , Gu Shengqing Stan , Han Ya , Qian Gege , Nicol Phillip , Zeng Zexian , Wang Chenfei , Tokheim Collin , Zhang Wubing , Fu Jingxin , Wang Jin , Nair Nishanth Ulhas , Rens Joost A.P. , Bourajjaj Meriem , Jansen Bas , Leenders Inge , Lemmers Jaap , Musters Mark , van Zanten Sanne , van Zelst Laura , Worthington Jenny , Liu Jun S. , Juric Dejan , Meyer Clifford A. , Oubrie Arthur , Liu X. Shirley , Fisher David E. , Flaherty Keith T.
Published: April 2023

Evaluation of bulk-BipotentR (BipotentR without single-cell sub-module).
Figure S10 from Discovery of Targets for Immune–Metabolic Antitumor Drugs Identifies Estrogen-Related Receptor Alpha
Authors: Sahu Avinash , Wang Xiaoman , Munson Phillip , Klomp Jan P.G. , Wang Xiaoqing , Gu Shengqing Stan , Han Ya , Qian Gege , Nicol Phillip , Zeng Zexian , Wang Chenfei , Tokheim Collin , Zhang Wubing , Fu Jingxin , Wang Jin , Nair Nishanth Ulhas , Rens Joost A.P. , Bourajjaj Meriem , Jansen Bas , Leenders Inge , Lemmers Jaap , Musters Mark , van Zanten Sanne , van Zelst Laura , Worthington Jenny , Liu Jun S. , Juric Dejan , Meyer Clifford A. , Oubrie Arthur , Liu X. Shirley , Fisher David E. , Flaherty Keith T.
Published: April 2023

Machine learning evaluation of immune-metabolic targets in predicting patient response to anti-PD1 monotherapy.
Figure S1 from Discovery of Targets for Immune–Metabolic Antitumor Drugs Identifies Estrogen-Related Receptor Alpha
Authors: Sahu Avinash , Wang Xiaoman , Munson Phillip , Klomp Jan P.G. , Wang Xiaoqing , Gu Shengqing Stan , Han Ya , Qian Gege , Nicol Phillip , Zeng Zexian , Wang Chenfei , Tokheim Collin , Zhang Wubing , Fu Jingxin , Wang Jin , Nair Nishanth Ulhas , Rens Joost A.P. , Bourajjaj Meriem , Jansen Bas , Leenders Inge , Lemmers Jaap , Musters Mark , van Zanten Sanne , van Zelst Laura , Worthington Jenny , Liu Jun S. , Juric Dejan , Meyer Clifford A. , Oubrie Arthur , Liu X. Shirley , Fisher David E. , Flaherty Keith T.
Published: April 2023

The description and validation of the BipotentR immune module
Supplementary Figures 1 - 7 from iNKT Cell Cytotoxic Responses Control T-Lymphoma Growth In Vitro and In Vivo
Authors: Bassiri Hamid , Das Rupali , Guan Peng , Barrett David M. , Brennan Patrick J. , Banerjee Pinaki P. , Wiener Susan J. , Orange Jordan S. , Brenner Michael B. , Grupp Stephan A. , Nichols Kim E.
Published: April 2023

PDF file - 713K, Figure S1. Kinetics of EL4 killing. Figure S2. iNKT cells kill several CD1d-expressing targets. Figure S3. EL4s express low levels of NKG2D ligands while iNKT and NK cells express NKG2D. Figure S4. Thymic but not splenic NKT cells kill EL4s in a GAg-dependent manner. Figure S5. DN3A4-1.2 NKT hybridoma cells kill GAg-loaded tumors. Figure S6. CD4+ and CD4- 8- liver iNKT cells possess cytotoxic capacity. Figure S7. iNKT cell reconstitution of NSG mice is not associated with in vivo accumulation of contaminating NK cells.
Figures S5 and S6 from Baseline Cytokine Profiles of Tuberculin-Specific CD4+ T Cells in Non–Muscle-Invasive Bladder Cancer May Predict Outcomes of BCG Immunotherapy
Authors: Jallad Samer , Thomas Philip , Newport Melanie J. , Kern Florian
Published: April 2023

Polyfunctional T-cell profiles
Supplementary Figures and Legends from Stereotactic Radiotherapy Increases Functionally Suppressive Regulatory T Cells in the Tumor Microenvironment
Authors: Muroyama Yuki , Nirschl Thomas R. , Kochel Christina M. , Lopez-Bujanda Zoila , Theodros Debebe , Mao Wendy , Carrera-Haro Maria A. , Ghasemzadeh Ali , Marciscano Ariel E. , Velarde Esteban , Tam Ada J. , Thoburn Christopher J. , Uddin Muniza , Meeker Alan K. , Anders Robert A. , Pardoll Drew M. , Drake Charles G.
Published: April 2023

Supplementary Figure 1: Radiotherapy suppresses tumor growth. Supplementary Figure 2: Characterization of the TME of B16/F10 tumors post-RT. Supplementary Figure 3: Stereotactic radiation does not change Treg in draining lymph nodes nor in spleens of treated mice. Supplementary Figure 4: Persistently increased Treg Post-RT. Supplementary Figure 5: Stereotactic radiation increases the suppressive markers of Treg in the RENCA tumor model. Supplementary Figure 6: Stereotactic radiation increases the suppressive markers of Treg in the MC38 tumor model. Supplementary Figure 7: Stereotactic radiation does not change the expression of the suppressive markers of Treg in DLNs. Supplementary Figure 8: Stereotactic radiation does not change the expression of the suppressive markers of Treg in spleens. Supplementary Figure 9: Expression of the selected markers of TIL-CD4+Foxp3- cells (Tconv) in the B16/F10 model. Supplementary Figure 10: Expression of the selected markers of TIL-CD4+Foxp3- cells (Tconv) in the RENCA model. Supplementary Figure 11: Expression of the selected markers of TIL-CD4+Foxp3- cells (Tconv) in the MC38 model. Supplementary Figure 12: Expression of 4-1BB on TIL-CD8+ cells. Supplementary Figure 13: The effect of TGF-beta blockade on different T cell subsets. Supplementary Figure 14: TGF-beta expression in the tumor microenvironment. Supplementary Figure 15: The effect of Fingolimod (FTY720) on peripheral blood lymphocytes counts. Supplementary Figure 16: Chemokine/cytokine expression of a selected panel in the tumor microenvironment post-radiation.
Supplementary Table 1 from Intravenous Injection of MVA Virus Targets CD8+ Lymphocytes to Tumors to Control Tumor Growth upon Combinatorial Treatment with a TLR9 Agonist
Authors: Fend Laetitia , Gatard-Scheikl Tanja , Kintz Jacqueline , Gantzer Murielle , Schaedler Emmanuelle , Rittner Karola , Cochin Sandrine , Fournel Sylvie , Préville Xavier
Published: April 2023

Supplementary Table 1. Inflammatory gene expression analysis in tumor bearing kidney.
Supplementary Figure 1 from Intravenous Injection of MVA Virus Targets CD8+ Lymphocytes to Tumors to Control Tumor Growth upon Combinatorial Treatment with a TLR9 Agonist
Authors: Fend Laetitia , Gatard-Scheikl Tanja , Kintz Jacqueline , Gantzer Murielle , Schaedler Emmanuelle , Rittner Karola , Cochin Sandrine , Fournel Sylvie , Préville Xavier
Published: April 2023

Supplementary Figure 1. CD3+ cells infiltration in tumor invasive margins.
Figure S7 from Antibody-Neutralized Reovirus Is Effective in Oncolytic Virotherapy
Authors: Berkeley Robert A. , Steele Lynette P. , Mulder Aat A. , van den Wollenberg Diana J.M. , Kottke Timothy J. , Thompson Jill , Coffey Matthew , Hoeben Rob C. , Vile Richard G. , Melcher Alan , Ilett Elizabeth J.
Published: April 2023

ReoNAb induce increased FcR RNA levels in monocytes
Data Supplement from Association Studies of Fcγ Receptor Polymorphisms with Outcome in HER2+ Breast Cancer Patients Treated with Trastuzumab in NCCTG (Alliance) Trial N9831
Authors: Norton Nadine , Olson Rebecca M. , Pegram Mark , Tenner Kathleen , Ballman Karla V. , Clynes Raphael , Knutson Keith L. , Perez Edith A.
Published: April 2023

Supplementary Table S1. Patient characteristics genotyped cohort vs non-genotyped cohort. Supplementary Table S2. Patient characteristics according to FCGR3A genotype. Supplementary Table S3. Patient characteristics according to FCGR2A genotype. Supplementary Table S4. Patient characteristics according to FCGR2B genotype. Supplementary Figure S1. DFS was not improved for any genotypic group in the trastuzumab-containing regimens.
Supplementary Table 1 from Radretumab Radioimmunotherapy in Patients with Brain Metastasis: A 124I-L19SIP Dosimetric PET Study
Authors: Poli Gian Luca , Bianchi Claudia , Virotta Giorgio , Bettini Anna , Moretti Renzo , Trachsel Eveline , Elia Giuliano , Giovannoni Leonardo , Neri Dario , Bruno Andrea
Published: April 2023

PDF file - 70K, 124I-dosimetry data to healthy organs.
Supplementary Figure Legend from PI3Kγ Activates Integrin α4 and Promotes Immune Suppressive Myeloid Cell Polarization during Tumor Progression
Authors: Foubert Philippe , Kaneda Megan M. , Varner Judith A.
Published: April 2023

S1. PI3Kgamma and integrin alpha4 inhibitors suppress tumor progression.
Supplementary Figure 1 from Phenotypic and Functional Activation of Hyporesponsive KIRnegNKG2Aneg Human NK-Cell Precursors Requires IL12p70 Provided by Poly(I:C)-Matured Monocyte-Derived Dendritic Cells
Authors: Curran Shane A. , Romano Emanuela , Kennedy Michael G. , Hsu Katharine C. , Young James W.
Published: April 2023

KIRnegNKG2Aneg cells comprise a distinct, phenotypically mature but functionally hyporesponsive subset of circulating bulk NK cells. (A) Representative flow cytometric contour plots (n=3) illustrate intracellular KIR and NKG2A expression on steady-state KIRpos and/or NKG2Apos (top panels) and KIRnegNKG2Aneg CD3negCD56pos NK cells (bottom panels). Antibody clones are shown in parenthesis. (B) Both KIRpos and/or NKG2Apos (shaded historgrams) and KIRnegNKG2Aneg cells (unshaded histograms) have a phenotypically mature surface phenotype. One representative experiment out of three is shown. Functional competence is compared between these two NK subsets based on (C) CD107a expression to detect cytotoxic degranulation (mean {plus minus} SD; n=5) and (D) intracellular IFN-gamma secretion (mean {plus minus} SD; n=5) after exposure to the NK sensitive LCL 721.221 cell line. **p=0.001-0.01; ***p<0.001.
Supplementary Figure Legend from Transient Complement Inhibition Promotes a Tumor-Specific Immune Response through the Implication of Natural Killer Cells
Authors: Janelle Valérie , Langlois Marie-Pierre , Tarrab Esther , Lapierre Pascal , Poliquin Laurent , Lamarre Alain
Published: April 2023

PDF file - 86K
Supplementary Figure from Caspase-1 from Human Myeloid-Derived Suppressor Cells Can Promote T Cell–Independent Tumor Proliferation
Authors: Zeng Qi , Fu Juan , Korrer Michael , Gorbounov Mikhail , Murray Peter J. , Pardoll Drew , Masica David L. , Kim Young J.
Published: April 2023

Supplementary Figure from Caspase-1 from Human Myeloid-Derived Suppressor Cells Can Promote T Cell–Independent Tumor Proliferation
Supplementary Figure 2 from TGFβ Inhibition Prior to Hypofractionated Radiation Enhances Efficacy in Preclinical Models
Authors: Young Kristina H. , Newell Pippa , Cottam Benjamin , Friedman David , Savage Talicia , Baird Jason R. , Akporiaye Emmanuel , Gough Michael J. , Crittenden Marka
Published: April 2023

Quantified effect of tumor size and epithelial-to-mesenchymal transition.
Supplementary Figure 1 from TGFβ Inhibition Prior to Hypofractionated Radiation Enhances Efficacy in Preclinical Models
Authors: Young Kristina H. , Newell Pippa , Cottam Benjamin , Friedman David , Savage Talicia , Baird Jason R. , Akporiaye Emmanuel , Gough Michael J. , Crittenden Marka
Published: April 2023

SM16 efficacy and radiosensitivity of CT26 and Panc02.
Supplementary Figure Legends from Apoptosis-Regulated Low-Avidity Cancer-Specific CD8+ T Cells Can Be Rescued to Eliminate HER2/neu–Expressing Tumors by Costimulatory Agonists in Tolerized Mice
Authors: Black Chelsea M. , Armstrong Todd D. , Jaffee Elizabeth M.
Published: April 2023

PDF file - 84K
Supplementary Figure 4 from Apoptosis-Regulated Low-Avidity Cancer-Specific CD8+ T Cells Can Be Rescued to Eliminate HER2/neu–Expressing Tumors by Costimulatory Agonists in Tolerized Mice
Authors: Black Chelsea M. , Armstrong Todd D. , Jaffee Elizabeth M.
Published: April 2023

PDF file - 71K, Percent of adoptively transferred low avidity T cells present in the mice compared between untreated mice and mice treated with Cy+vaccine and Cy+vaccine+OX40.
Supplementary Figure 1 from Apoptosis-Regulated Low-Avidity Cancer-Specific CD8+ T Cells Can Be Rescued to Eliminate HER2/neu–Expressing Tumors by Costimulatory Agonists in Tolerized Mice
Authors: Black Chelsea M. , Armstrong Todd D. , Jaffee Elizabeth M.
Published: April 2023

PDF file - 202K, Microarray data determining differences in gene expression between high and low avidity T cells.
Supplementary Figure 8 from Tumoral Immune Suppression by Macrophages Expressing Fibroblast Activation Protein-α and Heme Oxygenase-1
Authors: Arnold James N. , Magiera Lukasz , Kraman Matthew , Fearon Douglas T.
Published: April 2023

PDF file - 27K, Effect of HO inhibition on the expression of IFN-gamma and TNF-alpha.
Supplementary Figure 6 from Tumoral Immune Suppression by Macrophages Expressing Fibroblast Activation Protein-α and Heme Oxygenase-1
Authors: Arnold James N. , Magiera Lukasz , Kraman Matthew , Fearon Douglas T.
Published: April 2023

PDF file - 94K, HO-1 expressing FAP+ macrophages in transplanted PDA tumors.
Supplementary Figure 1 from Tumoral Immune Suppression by Macrophages Expressing Fibroblast Activation Protein-α and Heme Oxygenase-1
Authors: Arnold James N. , Magiera Lukasz , Kraman Matthew , Fearon Douglas T.
Published: April 2023

PDF file - 19K, Quantitation of FAP+/CD45+ cells in non immunogenic LL2 and immunogenic LL2/OVA tumors.
Supplementary Table 1 from Concurrent Radiotherapy and Ipilimumab Immunotherapy for Patients with Melanoma
Authors: Barker Christopher A. , Postow Michael A. , Khan Shaheer A. , Beal Kathryn , Parhar Preeti K. , Yamada Yoshiya , Lee Nancy Y. , Wolchok Jedd D.
Published: April 2023

PDF - 59KB, Frequency of immune-related adverse events (irAEs) in the present study and in a previous study.
Figure S1 from GITR Agonism Enhances Cellular Metabolism to Support CD8+ T-cell Proliferation and Effector Cytokine Production in a Mouse Tumor Model
Authors: Sabharwal Simran S. , Rosen David B. , Grein Jeff , Tedesco Dana , Joyce-Shaikh Barbara , Ueda Roanna , Semana Marie , Bauer Michele , Bang Kathy , Stevenson Christopher , Cua Daniel J. , Zúñiga Luis A.
Published: April 2023

Metabolic Inhibitors
Supplementary Figures 1 - 4 from BRAF Inhibition Alleviates Immune Suppression in Murine Autochthonous Melanoma
Authors: Steinberg Shannon M. , Zhang Peisheng , Malik Brian T. , Boni Andrea , Shabaneh Tamer B. , Byrne Katelyn T. , Mullins David W. , Brinckerhoff Constance E. , Ernstoff Marc S. , Bosenberg Marcus W. , Turk Mary Jo
Published: April 2023

Supplementary Figure 1: Vemurafenib arrests growth of Braf/Pten melanomas. Supplementary Figure 2: PLX4720 does not alter the character of CD4 helper T cells in the tumor microenvironment. Supplementary Figure 3: PLX4720 does not induce apoptosis of intratumoral myeloid cells. Supplementary Figure 4: Anti-CD8 depletes CD8 T cells in Braf/Pten tumors.
Supplementary Figure Legends from BRAF Inhibition Alleviates Immune Suppression in Murine Autochthonous Melanoma
Authors: Steinberg Shannon M. , Zhang Peisheng , Malik Brian T. , Boni Andrea , Shabaneh Tamer B. , Byrne Katelyn T. , Mullins David W. , Brinckerhoff Constance E. , Ernstoff Marc S. , Bosenberg Marcus W. , Turk Mary Jo
Published: April 2023

Supplementary Figure Legends from BRAF Inhibition Alleviates Immune Suppression in Murine Autochthonous Melanoma
Supplemental Table Legends from A Blueprint to Advance Colorectal Cancer Immunotherapies
Authors: Le Dung T. , Hubbard-Lucey Vanessa M. , Morse Michael A. , Heery Christopher R. , Dwyer Andrea , Marsilje Thomas H. , Brodsky Arthur N. , Chan Emily , Deming Dustin A. , Diaz Luis A. , Fridman Wolf H. , Goldberg Richard M. , Hamilton Stanley R. , Housseau Franck , Jaffee Elizabeth M. , Kang S. Peter , Krishnamurthi Smitha S. , Lieu Christopher H. , Messersmith Wells , Sears Cynthia L. , Segal Neil H. , Yang Arvin , Moss Rebecca A. , Cha Edward , O'Donnell-Tormey Jill , Roach Nancy , Davis Anjelica Q. , McAbee Keavy , Worrall Sharyn , Benson Al B.
Published: April 2023

Supplemental Tables 1 and 2
Supplementary Table 4 from Splenectomy Promotes Indirect Elimination of Intraocular Tumors by CD8+ T Cells That Is Associated with IFNγ- and Fas/FasL-Dependent Activation of Intratumoral Macrophages
Authors: Miller Maxine R. , Mandell Jonathan B. , Beatty Kelly M. , Harvey Stephen A.K. , Rizzo Michael J. , Previte Dana M. , Thorne Stephen H. , McKenna Kyle C.
Published: April 2023

Ingenuity Canonical Pathways.
Supplementary Figures 1 - 6 from Streptavidin: A Novel Immunostimulant for the Selection and Delivery of Autologous and Syngeneic Tumor Vaccines
Authors: Weir Chris , Hudson Amanda L. , Moon Elizabeth , Ross Angus , Alexander Miles , Peters Lyndsay , Langova Veronika , Clarke Stephen J. , Pavlakis Nick , Davey Ross , Howell Viive M.
Published: April 2023

PDF file - 263K, SI Figure 1: Tumor growth in rats treated with non-reduced tumor lysate versus control (Adjuvant only) in two separate experiments. SI Figure 2 : Interferon- and IL-4 levels in control and vaccine treated rats 21 days post tumour challenge. SI Figure 3: Vaccine (50) versus control (adjuvant only) in a repeat experiment and testing low dose streptavidin vaccine. SI Figure 4: C-Reactive protein and CIC-1 serum. SI Figure 5: Survival of rats vaccinated with vaccine produced using the canine vaccine production method versus control (adjuvant only). SI Figure 6: Electrophoretograms of the rat glioma and canine vaccines.
Supplementary Tables S1 and S2 from Tn-MUC1 DC Vaccination of Rhesus Macaques and a Phase I/II Trial in Patients with Nonmetastatic Castrate-Resistant Prostate Cancer
Authors: Scheid Elizabeth , Major Pierre , Bergeron Alain , Finn Olivera J. , Salter Russell D. , Eady Robin , Yassine-Diab Bader , Favre David , Peretz Yoav , Landry Claire , Hotte Sebastien , Mukherjee Som D. , Dekaban Gregory A. , Fink Corby , Foster Paula J. , Gaudet Jeffery , Gariepy Jean , Sekaly Rafick-Pierre , Lacombe Louis , Fradet Yves , Foley Ronan
Published: April 2023

Total and antigen-specific cumulative CD4+ (Table S1) and CD8+ (Table S2) cell mediated immune response observed after stimulation with DCs charged with KLH (KLH-DC), Tn-MUC1 (DC-Tn-MUC-1) or no protein as control (NP-DC) at various time points.
Supplementary Figure S1 from A Tet-On Inducible System for Controlling CD19-Chimeric Antigen Receptor Expression upon Drug Administration
Authors: Sakemura Reona , Terakura Seitaro , Watanabe Keisuke , Julamanee Jakrawadee , Takagi Erina , Miyao Kotaro , Koyama Daisuke , Goto Tatsunori , Hanajiri Ryo , Nishida Tetsuya , Murata Makoto , Kiyoi Hitoshi
Published: April 2023

pRetroX-TetOne vector sequence with CD19CAR and tEGFR
Supplementary Table 1 from Effector Regulatory T Cells Reflect the Equilibrium between Antitumor Immunity and Autoimmunity in Adult T-cell Leukemia
Authors: Ureshino Hiroshi , Shindo Takero , Nishikawa Hiroyoshi , Watanabe Nobukazu , Watanabe Eri , Satoh Natsuko , Kitaura Kazutaka , Kitamura Hiroaki , Doi Kazuko , Nagase Kotaro , Kimura Hiromi , Samukawa Makoto , Kusunoki Susumu , Miyahara Masaharu , Shin-I Tadasu , Suzuki Ryuji , Sakaguchi Shimon , Kimura Shinya
Published: April 2023

Adaptor ligation and PCR primer sequences
Supplementary Figure 1 from Effector Regulatory T Cells Reflect the Equilibrium between Antitumor Immunity and Autoimmunity in Adult T-cell Leukemia
Authors: Ureshino Hiroshi , Shindo Takero , Nishikawa Hiroyoshi , Watanabe Nobukazu , Watanabe Eri , Satoh Natsuko , Kitaura Kazutaka , Kitamura Hiroaki , Doi Kazuko , Nagase Kotaro , Kimura Hiromi , Samukawa Makoto , Kusunoki Susumu , Miyahara Masaharu , Shin-I Tadasu , Suzuki Ryuji , Sakaguchi Shimon , Kimura Shinya
Published: April 2023

Histopathological findings of the skin (Case 1)
Supplementary Figure S1 from IFNγ Induces DNA Methylation–Silenced GPR109A Expression via pSTAT1/p300 and H3K18 Acetylation in Colon Cancer
Authors: Bardhan Kankana , Paschall Amy V. , Yang Dafeng , Chen May R. , Simon Priscilla S. , Bhutia Yangzom D. , Martin Pamela M. , Thangaraju Muthusamy , Browning Darren D. , Ganapathy Vadivel , Heaton Christopher M. , Gu Keni , Lee Jeffrey R. , Liu Kebin
Published: April 2023

Figure S1. Silencing STAT1 diminishes IFN-gamma-induced GPR109A expression in human colon carcinoma cells.
Supplemental Methods from Checkpoint Blockade Immunotherapy Relies on T-bet but Not Eomes to Induce Effector Function in Tumor-Infiltrating CD8+ T Cells
Authors: Berrien-Elliott Melissa M. , Yuan Jinyun , Swier Lauryn E. , Jackson Stephanie R. , Chen Collin L. , Donlin Maureen J. , Teague Ryan M.
Published: April 2023

Contains qPCR probe and antibody information.
Supplementary Figure Legends from Adenosine Receptor 2A Blockade Increases the Efficacy of Anti–PD-1 through Enhanced Antitumor T-cell Responses
Authors: Beavis Paul A. , Milenkovski Nicole , Henderson Melissa A. , John Liza B. , Allard Bertrand , Loi Sherene , Kershaw Michael H. , Stagg John , Darcy Phillip K.
Published: April 2023

This document contains the Figure Legends for the Supplementary data Figures.
Supplementary Figure 9 from Adenosine Receptor 2A Blockade Increases the Efficacy of Anti–PD-1 through Enhanced Antitumor T-cell Responses
Authors: Beavis Paul A. , Milenkovski Nicole , Henderson Melissa A. , John Liza B. , Allard Bertrand , Loi Sherene , Kershaw Michael H. , Stagg John , Darcy Phillip K.
Published: April 2023

This supplementary Figure shows the phenotype and function of CD8+ T cells and tumor cells following A2A blockade single agent therapy.
Supplementary Figure 2 from Adenosine Receptor 2A Blockade Increases the Efficacy of Anti–PD-1 through Enhanced Antitumor T-cell Responses
Authors: Beavis Paul A. , Milenkovski Nicole , Henderson Melissa A. , John Liza B. , Allard Bertrand , Loi Sherene , Kershaw Michael H. , Stagg John , Darcy Phillip K.
Published: April 2023

This Supplementary Figure shows the expression of CD73 and adenosine receptors by tumor lines.
Supplementary Figure 5 from Adenovirus Improves the Efficacy of Adoptive T-cell Therapy by Recruiting Immune Cells to and Promoting Their Activity at the Tumor
Authors: Tähtinen Siri , Grönberg-Vähä-Koskela Susanna , Lumen Dave , Merisalo-Soikkeli Maiju , Siurala Mikko , Airaksinen Anu J. , Vähä-Koskela Markus , Hemminki Akseli
Published: April 2023

Supplementary Figure S5: Expression of immune checkpoint molecules negatively regulating T-cell function in tumors post-treatment.
Supplemental S-6 from The Inhibitory Signaling Receptor Protocadherin-18 Regulates Tumor-Infiltrating CD8+ T-cell Function
Authors: Frey Alan B.
Published: April 2023

Human Central memory T cells express pcdh18 coincident with in vitro conversion to Effector memory cells
Supplemental S-5 from The Inhibitory Signaling Receptor Protocadherin-18 Regulates Tumor-Infiltrating CD8+ T-cell Function
Authors: Frey Alan B.
Published: April 2023

IFNg secretion by human CD8+ naive T cells is not impacted by anti-pcdh18 amino terminal-specific Ab but is enhanced in CD8+ effector memory cells.
Supplementary Figure 2 from Adenovirus Improves the Efficacy of Adoptive T-cell Therapy by Recruiting Immune Cells to and Promoting Their Activity at the Tumor
Authors: Tähtinen Siri , Grönberg-Vähä-Koskela Susanna , Lumen Dave , Merisalo-Soikkeli Maiju , Siurala Mikko , Airaksinen Anu J. , Vähä-Koskela Markus , Hemminki Akseli
Published: April 2023

Supplementary Figure S2: Treatment schedule and phenotypic characterization of OT-I splenocytes before and after CD8a+ enrichment.
Supplemental S-4 from The Inhibitory Signaling Receptor Protocadherin-18 Regulates Tumor-Infiltrating CD8+ T-cell Function
Authors: Frey Alan B.
Published: April 2023

Antibody blockade of PD-1 or pcdh18 in wild type mice
Supplementary Table 2 from Endogenous Neoantigen-Specific CD8 T Cells Identified in Two Glioblastoma Models Using a Cancer Immunogenomics Approach
Authors: Johanns Tanner M. , Ward Jeffrey P. , Miller Christopher A. , Wilson Courtney , Kobayashi Dale K. , Bender Diane , Fu Yujie , Alexandrov Anton , Mardis Elaine R. , Artyomov Maxim N. , Schreiber Robert D. , Dunn Gavin P.
Published: April 2023

SMA-560 Composite
Supplementary Table 1 and Supplemental Figure Legends from Cisplatin Alters Antitumor Immunity and Synergizes with PD-1/PD-L1 Inhibition in Head and Neck Squamous Cell Carcinoma
Authors: Tran Linda , Allen Clint T. , Xiao Roy , Moore Ellen , Davis Ruth , Park So-Jin , Spielbauer Katie , Van Waes Carter , Schmitt Nicole C.
Published: April 2023

Supplemental Table 1: HNSCC cell lines were treated with a range of cisplatin doses for 72 hours, and cell death was assessed using an annexin/7AAD flow cytometry assay in at least two independent experiments performed in triplicate for each cell line. Cell death curves were generated to estimate the doses required to kill 25% (LD25) or 50% (LD50) for each cell line.
Supplemental Figure 4 from Cisplatin Alters Antitumor Immunity and Synergizes with PD-1/PD-L1 Inhibition in Head and Neck Squamous Cell Carcinoma
Authors: Tran Linda , Allen Clint T. , Xiao Roy , Moore Ellen , Davis Ruth , Park So-Jin , Spielbauer Katie , Van Waes Carter , Schmitt Nicole C.
Published: April 2023

S4. Moderate doses of cisplatin and anti-PD-1 do not cause significant kidney toxicity or hearing loss. A, kidneys were harvested from MOC1 tumor-bearing mice upon euthanasia, sectioned, and stained with H&E. Examples shown are representative of at least three different animals per treatment group. B and C, hearing was assessed in control or cisplatin-treated, MOC1 tumor-bearing mice after 6 weeks of treatment by measuring auditory brainstem response thresholds (B) and distortion product otoacoustic emission amplitudes (C). Data are mean (B) {plus minus} SEM (C) from two mice per group.
Supplementary Table 1 from Interleukin-6/STAT3 Pathway Signaling Drives an Inflammatory Phenotype in Group A Ependymoma
Authors: Griesinger Andrea M. , Josephson Rebecca J. , Donson Andrew M. , Mulcahy Levy Jean M. , Amani Vladimir , Birks Diane K. , Hoffman Lindsey M. , Furtek Steffanie L. , Reigan Phillip , Handler Michael H. , Vibhakar Rajeev , Foreman Nicholas K.
Published: April 2023

Experimentally determined STAT3 upregulated genes.
Supplementary Figure 5 from Interleukin-6/STAT3 Pathway Signaling Drives an Inflammatory Phenotype in Group A Ependymoma
Authors: Griesinger Andrea M. , Josephson Rebecca J. , Donson Andrew M. , Mulcahy Levy Jean M. , Amani Vladimir , Birks Diane K. , Hoffman Lindsey M. , Furtek Steffanie L. , Reigan Phillip , Handler Michael H. , Vibhakar Rajeev , Foreman Nicholas K.
Published: April 2023

S3I-201 effects on cell cycle EPN cell line 811 and apoptosis in EPN cell line 723.
Supplementary Figure 1 from Interleukin-6/STAT3 Pathway Signaling Drives an Inflammatory Phenotype in Group A Ependymoma
Authors: Griesinger Andrea M. , Josephson Rebecca J. , Donson Andrew M. , Mulcahy Levy Jean M. , Amani Vladimir , Birks Diane K. , Hoffman Lindsey M. , Furtek Steffanie L. , Reigan Phillip , Handler Michael H. , Vibhakar Rajeev , Foreman Nicholas K.
Published: April 2023

Consensus NMF of 81 primary ependymoma samples at k = 3 delineates two posterior fossa subgroups in the study cohort.
Supplementary Figure S2 from Targeting CD20+ Aggressive B-cell Non–Hodgkin Lymphoma by Anti-CD20 CAR mRNA-Modified Expanded Natural Killer Cells In Vitro and in NSG Mice
Authors: Chu Yaya , Hochberg Jessica , Yahr Ashlin , Ayello Janet , van de Ven Carmella , Barth Matthew , Czuczman Myron , Cairo Mitchell S.
Published: April 2023

Supplementary Fig.S2: nucleofection of anti-CD20 CAR mRNA does not affect the expression of endogenous receptors on exPBNK cells PBNK cells were expanded ex vivo by co-culturing PBMC with irradiated geK562 feeder cell lines in the presence of 40 IU/mL IL-2 for 14 days and isolated by depleting CD3+ T cells. The expanded NK cells were nucleofected with anti-CD20 CAR mRNA (CAR) or without anti-CD20 CAR mRNA (mock). CAR exPBNK or MOCK exPBNK cells were stained with indicated monoclonal antibodies. The expression of receptors on viable exPBNK Cells were compared by flow cytometry analysis.
Supplementary Table 2 from Extensive Profiling of the Expression of the Indoleamine 2,3-Dioxygenase 1 Protein in Normal and Tumoral Human Tissues
Authors: Théate Ivan , van Baren Nicolas , Pilotte Luc , Moulin Pierre , Larrieu Pierre , Renauld Jean-Christophe , Hervé Caroline , Gutierrez-Roelens Ilse , Marbaix Etienne , Sempoux Christine , Van den Eynde Benoît J.
Published: April 2023

Clinical characteristics of the patients analyzed for IDO1 expression in tumor-draining lymph nodes.
Supplementary Figure 1 from A Soluble Form of CD80 Enhances Antitumor Immunity by Neutralizing Programmed Death Ligand-1 and Simultaneously Providing Costimulation
Authors: Haile Samuel T. , Horn Lucas A. , Ostrand-Rosenberg Suzanne
Published: April 2023

PDF file - 1861K, Murine T cells express internal and cell surface CTLA-4 at 72 hrs. after activation.
Supplementary Figure 4 from Extensive Profiling of the Expression of the Indoleamine 2,3-Dioxygenase 1 Protein in Normal and Tumoral Human Tissues
Authors: Théate Ivan , van Baren Nicolas , Pilotte Luc , Moulin Pierre , Larrieu Pierre , Renauld Jean-Christophe , Hervé Caroline , Gutierrez-Roelens Ilse , Marbaix Etienne , Sempoux Christine , Van den Eynde Benoît J.
Published: April 2023

Proliferation of T cells stimulated with allogeneic dendritic cells expressing IDO1.
Supplemental Figure 2 from CTLA-4 Blockade Synergizes Therapeutically with PARP Inhibition in BRCA1-Deficient Ovarian Cancer
Authors: Higuchi Tomoe , Flies Dallas B. , Marjon Nicole A. , Mantia-Smaldone Gina , Ronner Lukas , Gimotty Phyllis A. , Adams Sarah F.
Published: April 2023

Combined treatment with the PARP-inhibitor and CTLA-4 antibody is effective in an orthotopic tumor model.
Supplementary Figure 2 from Extensive Profiling of the Expression of the Indoleamine 2,3-Dioxygenase 1 Protein in Normal and Tumoral Human Tissues
Authors: Théate Ivan , van Baren Nicolas , Pilotte Luc , Moulin Pierre , Larrieu Pierre , Renauld Jean-Christophe , Hervé Caroline , Gutierrez-Roelens Ilse , Marbaix Etienne , Sempoux Christine , Van den Eynde Benoît J.
Published: April 2023

Immunohistochemistry of a normal lung FFPE section with the anti-IDO1 antibody 4.16H1.
Supplementary Figure Legends from Induced PD-L1 Expression Mediates Acquired Resistance to Agonistic Anti-CD40 Treatment
Authors: Zippelius Alfred , Schreiner Jens , Herzig Petra , Müller Philipp
Published: April 2023

Supplementary Figure Legends
Supplementary Table 1 from Exome Sequencing to Predict Neoantigens in Melanoma
Authors: Pritchard Antonia L. , Burel Julie G. , Neller Michelle A. , Hayward Nicholas K. , Lopez J. Alejandro , Fatho Martina , Lennerz Volker , Wölfel Thomas , Schmidt Christopher W.
Published: April 2023

Cell line information and Sanger sequence confirmed mutations in each cell line.
Supplementary Figure 1B from Exome Sequencing to Predict Neoantigens in Melanoma
Authors: Pritchard Antonia L. , Burel Julie G. , Neller Michelle A. , Hayward Nicholas K. , Lopez J. Alejandro , Fatho Martina , Lennerz Volker , Wölfel Thomas , Schmidt Christopher W.
Published: April 2023

Raw scanned data from ELISpot plate scanning reader (AID ELISpot Reader Classic); data was then processed using the AID ELISpot software to standardise and analyse the spot counts using intensity and size measurements, to provide the final data presented in Supplementary Figure 2.
Supplementary Figure 2 from Efficacy of PD-1 Blockade Is Potentiated by Metformin-Induced Reduction of Tumor Hypoxia
Authors: Scharping Nicole E. , Menk Ashley V. , Whetstone Ryan D. , Zeng Xue , Delgoffe Greg M.
Published: April 2023

Metformin in the drinking water enhances PD-1 therapy in B16 melanoma.
Supplementary Figure S6 from Promoter Methylation Modulates Indoleamine 2,3-Dioxygenase 1 Induction by Activated T Cells in Human Breast Cancers
Authors: Noonepalle Satish K. , Gu Franklin , Lee Eun-Joon , Choi Jeong-Hyeon , Han Qimei , Kim Jaejik , Ouzounova Maria , Shull Austin Y. , Pei Lirong , Hsu Pei-Yin , Kolhe Ravindra , Shi Fang , Choi Jiseok , Chiou Katie , Huang Tim H.M. , Korkaya Hasan , Deng Libin , Xin Hong-Bo , Huang Shuang , Thangaraju Muthusamy , Sreekumar Arun , Ambs Stefan , Tang Shou-Ching , Munn David H. , Shi Huidong
Published: April 2023

The promoter region of IDO1 is differentially methylated between breast luminal epithelial and myoepithelial cells in Roadmap Epigenome data.
Supplementary Figure S5 from Promoter Methylation Modulates Indoleamine 2,3-Dioxygenase 1 Induction by Activated T Cells in Human Breast Cancers
Authors: Noonepalle Satish K. , Gu Franklin , Lee Eun-Joon , Choi Jeong-Hyeon , Han Qimei , Kim Jaejik , Ouzounova Maria , Shull Austin Y. , Pei Lirong , Hsu Pei-Yin , Kolhe Ravindra , Shi Fang , Choi Jiseok , Chiou Katie , Huang Tim H.M. , Korkaya Hasan , Deng Libin , Xin Hong-Bo , Huang Shuang , Thangaraju Muthusamy , Sreekumar Arun , Ambs Stefan , Tang Shou-Ching , Munn David H. , Shi Huidong
Published: April 2023

IDO1 promoter is hypomethylated in ER- and basal-like BC subtypes based on analysis of TCGA data
Supplementary Figure S4 from Promoter Methylation Modulates Indoleamine 2,3-Dioxygenase 1 Induction by Activated T Cells in Human Breast Cancers
Authors: Noonepalle Satish K. , Gu Franklin , Lee Eun-Joon , Choi Jeong-Hyeon , Han Qimei , Kim Jaejik , Ouzounova Maria , Shull Austin Y. , Pei Lirong , Hsu Pei-Yin , Kolhe Ravindra , Shi Fang , Choi Jiseok , Chiou Katie , Huang Tim H.M. , Korkaya Hasan , Deng Libin , Xin Hong-Bo , Huang Shuang , Thangaraju Muthusamy , Sreekumar Arun , Ambs Stefan , Tang Shou-Ching , Munn David H. , Shi Huidong
Published: April 2023

Immunoblots reveals that treatments with ruxolitinib blocked STAT1-mediated IDO expression.
Supplementary Figure S3 from Promoter Methylation Modulates Indoleamine 2,3-Dioxygenase 1 Induction by Activated T Cells in Human Breast Cancers
Authors: Noonepalle Satish K. , Gu Franklin , Lee Eun-Joon , Choi Jeong-Hyeon , Han Qimei , Kim Jaejik , Ouzounova Maria , Shull Austin Y. , Pei Lirong , Hsu Pei-Yin , Kolhe Ravindra , Shi Fang , Choi Jiseok , Chiou Katie , Huang Tim H.M. , Korkaya Hasan , Deng Libin , Xin Hong-Bo , Huang Shuang , Thangaraju Muthusamy , Sreekumar Arun , Ambs Stefan , Tang Shou-Ching , Munn David H. , Shi Huidong
Published: April 2023

Snapshots of IDO1 RNA-seq tracks in UCSC genome browser.
Supplementary Figure 7 from Intratumoral CD3 and CD8 T-cell Densities Associated with Relapse-Free Survival in HCC
Authors: Gabrielson Andrew , Wu Yunan , Wang Hongkun , Jiang Jiji , Kallakury Bhaskar , Gatalica Zoran , Reddy Sandeep , Kleiner David , Fishbein Thomas , Johnson Lynt , Island Eddie , Satoskar Rohit , Banovac Filip , Jha Reena , Kachhela Jaydeep , Feng Perry , Zhang Tiger , Tesfaye Anteneh , Prins Petra , Loffredo Christopher , Marshall John , Weiner Louis , Atkins Michael , He Aiwu Ruth
Published: April 2023

Bivariate analysis of CD3+ and CD8+ cell density and beta-catenin expression.
Supplementary Figure S2 from Promoter Methylation Modulates Indoleamine 2,3-Dioxygenase 1 Induction by Activated T Cells in Human Breast Cancers
Authors: Noonepalle Satish K. , Gu Franklin , Lee Eun-Joon , Choi Jeong-Hyeon , Han Qimei , Kim Jaejik , Ouzounova Maria , Shull Austin Y. , Pei Lirong , Hsu Pei-Yin , Kolhe Ravindra , Shi Fang , Choi Jiseok , Chiou Katie , Huang Tim H.M. , Korkaya Hasan , Deng Libin , Xin Hong-Bo , Huang Shuang , Thangaraju Muthusamy , Sreekumar Arun , Ambs Stefan , Tang Shou-Ching , Munn David H. , Shi Huidong
Published: April 2023

A subset of primary breast tumors expresses a 308-gene signature that correlated with gene signatures specifically expressed in immune cells.
Supplementary Figure Legends from Promoter Methylation Modulates Indoleamine 2,3-Dioxygenase 1 Induction by Activated T Cells in Human Breast Cancers
Authors: Noonepalle Satish K. , Gu Franklin , Lee Eun-Joon , Choi Jeong-Hyeon , Han Qimei , Kim Jaejik , Ouzounova Maria , Shull Austin Y. , Pei Lirong , Hsu Pei-Yin , Kolhe Ravindra , Shi Fang , Choi Jiseok , Chiou Katie , Huang Tim H.M. , Korkaya Hasan , Deng Libin , Xin Hong-Bo , Huang Shuang , Thangaraju Muthusamy , Sreekumar Arun , Ambs Stefan , Tang Shou-Ching , Munn David H. , Shi Huidong
Published: April 2023

Figure Legends for Supplementary Figures 1-6
Supplementary Figure 3 from Intratumoral CD3 and CD8 T-cell Densities Associated with Relapse-Free Survival in HCC
Authors: Gabrielson Andrew , Wu Yunan , Wang Hongkun , Jiang Jiji , Kallakury Bhaskar , Gatalica Zoran , Reddy Sandeep , Kleiner David , Fishbein Thomas , Johnson Lynt , Island Eddie , Satoskar Rohit , Banovac Filip , Jha Reena , Kachhela Jaydeep , Feng Perry , Zhang Tiger , Tesfaye Anteneh , Prins Petra , Loffredo Christopher , Marshall John , Weiner Louis , Atkins Michael , He Aiwu Ruth
Published: April 2023

ImageJ plug-in code for image analysis.
Suppl Figure 2 from Prognostic Significance of PD-L1+ and CD8+ Immune Cells in HPV+ Oropharyngeal Squamous Cell Carcinoma
Authors: Solomon Benjamin , Young Richard J. , Bressel Mathias , Urban Damien , Hendry Shona , Thai Alesha , Angel Christopher , Haddad Afaf , Kowanetz Marcin , Fua Tsien , Corry June , Fox Stephen , Rischin Danny
Published: April 2023

p16 OS KM curves
Supplementary Figure S3. Gene expression in ADU-S100 treated tumors from neu/N mice. from A STING Agonist Given with OX40 Receptor and PD-L1 Modulators Primes Immunity and Reduces Tumor Growth in Tolerized Mice
Authors: Foote Jeremy B. , Kok Marleen , Leatherman James M. , Armstrong Todd D. , Marcinkowski Bridget C. , Ojalvo Laureen S. , Kanne David B. , Jaffee Elizabeth M. , Dubensky Thomas W. , Emens Leisha A.
Published: April 2023

(A) 162 differentially expressed genes (Affymetrix Mouse Gene 2.0 ST array, 3 independent experiments, ANOVA p<0.05 and at least 2 fold change) induced by ADU-S100 IT injection on day 1 in tolerant neu/N mice. (B) The five most significant canonical pathways (Ingenuity Pathway Analysis) enriched 1 day after ADU-S100 IT injection in tolerant neu/N mice. P-values calculated using Fisher''s exact test. The orange points represent the ratio between the number of genes induced by IT ADU-S100 that belong to that specific pathway by the total number of genes annotated to that specific pathway. (C) Average mRNA values of C-C chemokines and CXC chemokines 1 and 7 days after IT ADU-S100 in tolerant neu/N mice. P-values calculated using ANOVA.
Video 1 from Phage-Based Anti-HER2 Vaccination Can Circumvent Immune Tolerance against Breast Cancer
Authors: Bartolacci Caterina , Andreani Cristina , Curcio Claudia , Occhipinti Sergio , Massaccesi Luca , Giovarelli Mirella , Galeazzi Roberta , Iezzi Manuela , Tilio Martina , Gambini Valentina , Wang Junbiao , Marchini Cristina , Amici Augusto
Published: April 2023

In silico simulation comparing wtHER2 vs delta16HER2. This video simulates the different dynamic behavior of wild type HER2 protein and its splice variant delta16HER2 once inserted into a virtual cellular membrane.
Supplementary S1 from Phage-Based Anti-HER2 Vaccination Can Circumvent Immune Tolerance against Breast Cancer
Authors: Bartolacci Caterina , Andreani Cristina , Curcio Claudia , Occhipinti Sergio , Massaccesi Luca , Giovarelli Mirella , Galeazzi Roberta , Iezzi Manuela , Tilio Martina , Gambini Valentina , Wang Junbiao , Marchini Cristina , Amici Augusto
Published: April 2023

Characterization of IgGs yielded from DNA vaccination by means of cellular ELISA
Supplementary Table 2 from A High-Throughput Immune-Oncology Screen Identifies EGFR Inhibitors as Potent Enhancers of Antigen-Specific Cytotoxic T-lymphocyte Tumor Cell Killing
Authors: Lizotte Patrick H. , Hong Ruey-Long , Luster Troy A. , Cavanaugh Megan E. , Taus Luke J. , Wang Stephen , Dhaneshwar Abha , Mayman Naomi , Yang Aaron , Kulkarni Meghana , Badalucco Lauren , Fitzpatrick Erica , Kao Hsiang-Fong , Kuraguchi Mari , Bittinger Mark , Kirschmeier Paul T. , Gray Nathanael S. , Barbie David A. , Jänne Pasi A.
Published: April 2023

Table 2 sgRNA genes and sequences
Supplementary Table S1 from CAR-T Cells Surface-Engineered with Drug-Encapsulated Nanoparticles Can Ameliorate Intratumoral T-cell Hypofunction
Authors: Siriwon Natnaree , Kim Yu Jeong , Siegler Elizabeth , Chen Xianhui , Rohrs Jennifer A. , Liu Yarong , Wang Pin
Published: April 2023

DNA sequences of primers and plasmids
Supplementary Figures from A Synthetic DNA, Multi-Neoantigen Vaccine Drives Predominately MHC Class I CD8+ T-cell Responses, Impacting Tumor Challenge
Authors: Duperret Elizabeth K. , Perales-Puchalt Alfredo , Stoltz Regina , G.H. Hiranjith , Mandloi Nitin , Barlow James , Chaudhuri Amitabha , Sardesai Niranjan Y. , Weiner David B.
Published: April 2023

Supplementary Figures S1-8
Legend for supplementary figures from CAR-T Cells Surface-Engineered with Drug-Encapsulated Nanoparticles Can Ameliorate Intratumoral T-cell Hypofunction
Authors: Siriwon Natnaree , Kim Yu Jeong , Siegler Elizabeth , Chen Xianhui , Rohrs Jennifer A. , Liu Yarong , Wang Pin
Published: April 2023

Figure legends
Figure S7 from Intratumoral STING Activation with T-cell Checkpoint Modulation Generates Systemic Antitumor Immunity
Authors: Ager Casey R. , Reilley Matthew J. , Nicholas Courtney , Bartkowiak Todd , Jaiswal Ashvin R. , Curran Michael A.
Published: April 2023

TIL flow population quantifications
Figure S6 from A CS1-NKG2D Bispecific Antibody Collectively Activates Cytolytic Immune Cells against Multiple Myeloma
Authors: Chan Wing Keung , Kang Siwen , Youssef Youssef , Glankler Erin N. , Barrett Emma R. , Carter Alex M. , Ahmed Elshafa H. , Prasad Aman , Chen Luxi , Zhang Jianying , Benson Don M. , Caligiuri Michael A. , Yu Jianhua
Published: April 2023

ELISA for quantification of free bound CS1-NKG2D biAb in plasma samples
Figure S3 from A CS1-NKG2D Bispecific Antibody Collectively Activates Cytolytic Immune Cells against Multiple Myeloma
Authors: Chan Wing Keung , Kang Siwen , Youssef Youssef , Glankler Erin N. , Barrett Emma R. , Carter Alex M. , Ahmed Elshafa H. , Prasad Aman , Chen Luxi , Zhang Jianying , Benson Don M. , Caligiuri Michael A. , Yu Jianhua
Published: April 2023

IFN-gamma production by PBMCs without a co-stimulation or co-stimulated by IL-2 upon recognition of MM.1S in the presence of control biAb and CS1-NKG2D biAb